APA aipamena

Fala, L. (2016). Entresto (Sacubitril/Valsartan): First-in-Class Angiotensin Receptor Neprilysin Inhibitor FDA Approved for Heart Failure. Am Health Drug Benefits.

Chicago Style aipamena

Fala, Loretta. "Entresto (Sacubitril/Valsartan): First-in-Class Angiotensin Receptor Neprilysin Inhibitor FDA Approved for Heart Failure." Am Health Drug Benefits 2016.

MLA aipamena

Fala, Loretta. "Entresto (Sacubitril/Valsartan): First-in-Class Angiotensin Receptor Neprilysin Inhibitor FDA Approved for Heart Failure." Am Health Drug Benefits 2016.

Kontuz: berrikusi erreferentzia hauek erabili aurretik.